Every 10-Q that PETROS PHARM INC (PTPI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PTPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTPI filings page.
Petros Pharmaceuticals, Inc. reported no continuing revenues for the three and six months ended June 30, 2026, reflecting its exit from Stendra and VEDs and pivot to developing an Rx-to-OTC switch technology platform. Selling, general and administrative expenses fell to $2.0 million for the first half of 2026 from $3.3 million in 2025, narrowing the loss from continuing operations to $1.9 million from $3.2 million. For the quarter, SG&A was $1.0 million versus $1.8 million, with loss from continuing operations of $1.0 million.
Cash and cash equivalents were $3.5 million with working capital of about $0.7 million, and operating activities used $1.6 million of cash in the first half. The company discloses substantial doubt about its ability to continue as a going concern and is evaluating equity and debt financings. It remains burdened by $2.5 million of accrued Series A preferred payments and a large warrant overhang of about 2.6 billion warrants at low exercise prices. Following a Nasdaq delisting in 2025, its common stock trades on the OTC market while management advances its early-stage ACNU-oriented SaaS/SaMD platform.
Petros Pharmaceuticals reported a smaller loss in Q1 2026 but remains under significant financial strain. The company had no continuing revenue and recorded a net loss of $987,036, improved from $2,260,022 a year earlier, helped by lower selling, general and administrative expenses, which fell about 30% to $1,027,179. Cash used in operating activities was $784,272, leaving cash and cash equivalents of $4,352,450 and working capital of about $1.8M as of March 31, 2026. Management states the company does not have sufficient liquidity to fund operations for the next 12 months and discloses “substantial doubt” about its ability to continue as a going concern. Petros has exited its historical erectile‑dysfunction drug and device businesses and is now an early‑stage platform developer focused on Rx‑to‑OTC switch and ACNU technologies, while its common stock trades on the OTC market following delisting from Nasdaq.
Petros Pharmaceuticals (PTPI) filed its Q3 2025 10‑Q. The company exited legacy products, recorded a $6.97 million gain from assigning subsidiaries and a Vivus settlement, and reported nine‑month net income of $2.25 million. From continuing operations, it posted a loss of $4.16 million; large preferred-related deemed dividends and warrant items drove a nine‑month loss per share of $1.95.
Liquidity remains tight: cash was $6,070,266 and working capital was $3.4 million as of September 30, 2025, with substantial doubt about continuing as a going concern. Stockholders’ equity improved to $3,368,087 from a deficit at year‑end 2024. A February 2025 financing raised $9.6 million gross (about $8.5 million net). The company effected a 1‑for‑25 reverse split on April 30, 2025, and its common stock was delisted from Nasdaq and now trades on the OTC Market.
Capital structure shifted materially: investors exercised Series B warrants via alternative cashless exercise for 39,208,828 shares during the period. Common shares outstanding were 42,284,502 at September 30, 2025, and 42,372,260 as of November 12, 2025.